A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative Colitis
PMID: 39694207
Source: Clin Gastroenterol Hepatol
Publication date:
2025-07-24
Year:
2025
Abstract
NULL